Articles tagged with Vaccine Development
A new study by University of Missouri biochemist Steven Van Doren reveals the fusion peptide's crucial role in virus attachment and cell penetration. This research could inform the development of more effective vaccines capable of fighting all types of coronavirus infections.
Scientists have established the effectiveness of vaccines against leishmaniasis in animal studies, revealing specific molecular-level changes in host cells. The vaccines, created using mutated parasites, prompt distinct immune responses in hosts, offering new insights into their mechanisms and potential applications.
A new AI-powered triage platform uses machine learning and metabolomics data to predict patient disease severity and length of hospitalization during a viral outbreak. The platform integrates routine clinical data, patient comorbidity information, and untargeted plasma metabolomics data to drive its predictions.
Researchers at the University of Montana are developing vaccines to prevent fentanyl and heroin drug overdoses. The first vaccine will target heroin, followed by a fentanyl vaccine in Phase I clinical trials. The vaccines aim to elicit antibodies against target opioids while sparing critical medications used in opioid addiction treatment.
A new essay highlights how news stories about healthcare workers during COVID-19 often left out crucial socioeconomic and environmental contexts, which can impact consumer thoughts and responses. By introducing a public health framework, experts aim to broaden storytelling and reframed scientific information dissemination.
Researchers from the University of Kansas have created a powerful dataset to facilitate drug development against gram-negative bacteria. The dataset reveals over 270,000 previously unidentified outer-membrane proteins with potential as vaccine targets.
A new study finds SARS-CoV-2 infection significantly associated with development of high blood pressure in hospitalized adults. Persistent high blood pressure was more common in people with COVID-19 than influenza, highlighting potential long-term cardiovascular risk.
Researchers found that vaccines against tetanus, diphtheria, and shingles, as well as pneumococcus, may reduce the risk of developing Alzheimer’s disease by 25-30% in adults over 65. Vaccination is hypothesized to change how the immune system responds to toxic proteins contributing to Alzheimer’s disease.
A new Northwestern Medicine study measures resilience in biomedical scientists during COVID-19, revealing that resiliency did not guarantee career advancement. The study found that women scientists faced greater household responsibilities and social pressure to advance their careers, leading to significant career setbacks.
A new machine-learning method, BigMHC, can accurately predict cancer-related protein fragments that may trigger an immune system response. By leveraging massive data through transfer learning, BigMHC enables scientists to develop personalized immunotherapies and vaccines by identifying the most likely to provoke an immune response.
QUT researchers have created a booster vaccine using implant technology to protect wild koalas from Chlamydia disease. The new device allows for in-the-field vaccination without recapturing the animals, reducing human interference and increasing vaccination efficiency.
The Access to Advanced Health Institute has received an $18 million award from the NIH to develop a temperature-stable, single-dose chikungunya RNA vaccine candidate. The vaccine uses innovative RNA platform technology to protect against the virus, which causes debilitating joint and muscle pain in endemic areas.
A University of Ottawa-led research team has made significant progress in understanding XLP-2, a genetic disorder that affects the immune system. The study reveals two underlying mechanisms: poor expression of Interleukin-6 and compromised T cell survival, which lead to immunodeficiency in patients.
Biologists argue that building on genomic sequencing momentum is critical in society's response to future pandemics. The technology improved during the COVID-19 pandemic, but gaps remain in global infrastructure and data sharing.
Researchers discovered a protective immune feature lacking in people chronically infected with intestinal worms, leading to potential human vaccines and treatments. The study used animal models and found that blocking the T follicular helper response impaired worm clearance and promoted chronic infection.
A novel Raman technique called thermostable-Raman-interaction-profiling (TRIP) allows for label-free and highly reproducible Raman spectroscopy measurements, breaking a 50-year-old challenge. The TRIP method enables the detection of protein-ligand interactions in real-time, potentially shortening drug and vaccine testing timelines.
Researchers developed a novel vaccine against SARS-CoV-2 by selecting antigen variants with low binding affinity, resulting in higher neutralizing antibody concentrations. This design strategy may also improve vaccine efficacy for other coronaviruses and herpes viruses.
Scientists at the University of Pittsburgh Center for Vaccine Research have identified a protein responsible for lethal liver disease in mice infected with Rift Valley fever virus. Removing this protein, Lrp1, from the liver prevented viral replication and extended mouse lifespan.
Researchers have developed a computational tool to compare large datasets and predict immune responses to disease, potentially leading to better vaccines. The new algorithm, designed by La Jolla Institute for Immunology scientists, uses machine learning to identify underlying patterns in immune system data.
Researchers developed a bioinformatic tool that selects parts of proteins to elicit strong immune responses. This approach, grounded in immunological theory, was four times more efficient than current methods, suggesting better vaccine protection against diseases.
A study led by UCSF researchers discovered that people who remain asymptomatic after contracting COVID-19 often carry a specific gene variation that helps their immune system recognize the virus. This mutation, HLA-B*15:01, is common among asymptomatic individuals and can also help those with symptoms to recover more quickly.
CEPI and HMRI collaborate to leverage AI technology for faster vaccine development. The partnership aims to identify epitopes that stimulate the immune system, enabling swift clinical testing.
Researchers at MIT are developing a continuous mRNA manufacturing platform to improve vaccine development and production. The pilot-scale system aims to reduce costs, increase efficiency, and facilitate collaboration in the biopharmaceutical industry.
A novel biomaterials-based approach enhances adoptive T cell therapy with cancer vaccine technology, providing strong and long-lasting effects against solid tumors. In mice carrying melanomas, SIVET enables fast tumor shrinking and long-term protection.
A survey of 2,000 German adults found that people with higher levels of empathy and cosmopolitanism are more likely to prioritize sharing vaccine supplies internationally. The study suggests that there is substantial public support for international vaccine solidarity when infection rates are at a modest level and falling.
The IBS-KAI Conference will focus on viral diseases and immunology, featuring over 20 international experts. The conference aims to prepare for responses to future infectious diseases, including those with pandemic potentials.
A vaccine originally developed to prevent bacteria-caused diarrhea has been found to also help infant nonhuman primates grow faster, according to a new study. The researchers found that vaccinated baby monkeys were taller than the unvaccinated when measured from head to toe, with a significant improvement in growth rate.
Researchers have developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA. This 'Purecap' technique extracted up to 100% pure Cap2-type mRNA, which showed improved protein production and lower immunostimulatory activity.
A new study from the University of Missouri-Columbia found that supportive communities and education about breastfeeding health benefits can boost breastfeeding rates, particularly in rural areas where it is less common. The study also showed that reduced stigma surrounding breastfeeding occurred with increased community exposure.
Researchers at Tel Aviv University have developed a novel approach to fight cancer by inducing cancer cells to produce a toxic protein using mRNA molecules. The treatment was successful in eliminating 44-60% of cancer cells in animal models, with no damage to healthy cells.
A University of Queensland developed vaccine will protect farmed saltwater crocodiles from West Nile virus (WNV), providing economic benefits worth $10million per year. The vaccine is the first of its kind to achieve proven safety and efficacy in crocodiles, with a robust immune response induced after two doses.
Researchers have isolated and analyzed individual immune cells targeting the hepatitis C virus, providing valuable data for vaccine development. The study found that antiviral treatment reduces cytotoxicity in HCV-specific immune cells, offering a potential pathway to an effective vaccine.
Researchers identified four therapeutic monoclonal antibody candidates that neutralized a range of SARS-CoV-2 variants. Prolonged exposure to the virus triggered somatic hypermutations, equipping these antibodies with an extensive binding interface.
Researchers found that an iron-rich diet can prevent deadly symptoms in mice during active infection, while a functional adaptive immune system is required for immunity against future infections. The study paves the way for the development of new vaccines that could promote immunity for those with diarrheal diseases.
A new rapid viral plaque detection system enabled by holography and deep learning can help accelerate vaccine and drug development. The system reduces the detection time of traditional viral plaque assays by up to 48 hours, eliminating chemical staining and manual counting.
The study developed multi-valent mRNA vaccines targeting monkeypox enveloped or mature viron surface antigens, inducing dynamic immune responses with robust IgG and neutralizing activities. The vaccines protected a mouse model from lethal VACV challenge.
A German federal funding program will support a five-year research collaboration to develop specialty lipids and auxiliaries for mRNA vaccines. The project aims to enhance production capacities and improve the resilience of supply chains for future mRNA therapeutics.
Scientists at UCSF and NIBSC have developed two new oral polio vaccines with genetically engineered weakened poliovirus to reduce reversion to dangerous forms. These vaccines aim to boost the World Health Organization's efforts to eradicate polio, which has persisted despite successful international vaccination campaigns.
CHOP researchers have developed stable, universal MHC-I molecules that can be produced rapidly at scale, allowing for the development of effective and universal immunotherapies. These engineered MHC-I molecules promote peptide exchange across multiple HLA allotypes, covering various forms.
Researchers at Karolinska Institutet have developed a new method called single-particle profiling (SPP) to study bioparticles in health and disease. The SPP enables the measurement of thousands of particles between 5 and 200 nanometres in size, with potential applications in vaccine development and creating more effective nanocarriers.
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.
A study of 17,000 people across eight African countries found a decline in vaccine confidence, particularly for COVID-19 vaccines. The drop in routine childhood vaccinations has led to six million fewer children receiving life-saving shots, putting decades of progress at risk.
Nebraska scientists have made significant progress in developing a safe and effective long-lasting swine flu vaccine. The Epigraph algorithm enables the creation of a universal flu vaccine that protects against multiple types of influenza viruses for at least one year and is suitable for all age groups.
Researchers found that boosting vaccine use can reduce lockdown intensity and duration, but the relationship varies based on factors like disease severity and vaccination speed. The study suggests a nuanced approach to balancing lockdowns and vaccinations in future pandemics.
A Johns Hopkins Medicine-led team identified protein fragments that stimulate the immune system to recognize and attack HIV. The study's technique, called reductionist cell-free antigen processing, replicates the complex events in the human immune system, enabling the identification of immunodominant epitopes.
A nationwide study of nearly 10,000 adults identifies 12 hallmarks of long COVID, including debilitating fatigue, loss of smell or taste, and gastrointestinal symptoms. The findings provide a new scoring system for clinicians to define and investigate treatments for patients with long COVID.
The study, published in Science Translational Medicine, shows robust T-cell responses in volunteers participating in a phase 1 clinical trial of a self-assembling nanoparticle HIV vaccine. The antigen used stimulates VRC01-class B cells, an immune response considered promising for boosting in further studies.
Researchers at UNC School of Medicine discovered that human T cells can independently control RSV replication in lung tissue, suggesting a new approach to developing vaccines. The study's findings support the development of RSV vaccines that elicit effective T cell responses to improve vaccine efficacy.
Research reveals that age-dependent changes in germinal centres lead to reduced vaccine response in older people. The study demonstrates that reversing these changes can be achieved through interventions.
A new study investigates lockdowns and vaccines' complementary or substitutive roles in mitigating COVID-19's effects. The researchers found that vaccinations should be relaxed after substantial vaccination rates, but vastly different policies may be optimal depending on parameters.
A clinical trial has started enrolling volunteers to test the experimental H1ssF-3928 mRNA-LNP vaccine, developed by NIAID's Vaccine Research Center, for its safety and ability to induce an immune response. The trial aims to find an optimal dosage and compare it with a current seasonal flu vaccine.
A recent study by Monash University researchers found that a unique subtype of an immune cell produces long-lasting antibodies in response to certain vaccinations. This discovery may lead to the development of improved vaccines providing life-long protection.
Researchers found that Fiocruz's partnership with AstraZeneca was crucial to the success of COVID-19 vaccine production in Brazil. The partnership demonstrated the importance of technology transfer agreements, regulatory support, and political skill. Bio-Manguinhos facility played a significant role in producing vaccines, making over 5...
Researchers at the University of Missouri identified occludin protein as a mediator for cell-to-cell transmission of coronavirus. The study found that damaged occludin protein enables virus replication and spread to neighboring cells, worsening symptoms.
The International Vaccine Institute (IVI) has started clinical development of DuoChol, a new oral cholera vaccine in capsule form. This innovation offers improved thermostability, reducing storage challenges, while making vaccines more accessible to those who need them most.
The University of Liverpool is conducting a Phase I trial of a new Zika virus vaccine designed for pregnant women, which has shown promising results in animal studies. The vaccine aims to generate highly protective and long-lasting immunity against the mosquito-borne virus that can cause severe foetal birth defects.
A world-leading international trial has found that the BCG vaccine does not protect healthcare workers against COVID-19, despite boosting 'front-line' immunity in infants and protecting against respiratory infections. The research involved 3988 healthcare workers and showed a higher risk of symptomatic COVID-19 in the BCG group.
The NIH is conducting a clinical trial to evaluate the JYNNEOS mpox vaccine's safety and immune response in adolescents aged 12-17. The trial, launched at George Washington University, aims to determine if the vaccine can protect teens from this painful and sometimes deadly disease.
A new vaccine type, mRNA-4157/V940, added to immunotherapy significantly reduced melanoma recurrence and death rates. The combination was found to be effective in 22.4% of patients compared to 40% without the vaccine.
The primary COVID-19 vaccines provided adequate protection against transmission, hospitalization, and death, but their effectiveness waned in the face of the Omicron variant. The study found that vaccines developed prior to Omicron's emergence were 83% effective against infection at baseline, but this decreased to 47% by 40 weeks.